Thomas Golper
Last active: 4/25/2016

Profile

Thomas A. Golper, MD, FACP trained at Indiana University and the Oregon Health Sciences University, and currently is Professor of Medicine (Nephrology) at Vanderbilt University Medical Center in Nashville, TN. He has held positions on the Board of Directors of the RPA and AAKP, served as the PD Adequacy Work Group Chair for the first two versions of KDOQI, and remains on the Work Group. He led the Network 9 Peritonitis and Catheter Survival Study and has served on the ISPD Ad Hoc Committee for Peritonitis for many iterations of its guidelines. His interests remain in the field of dialysis and the administrative aspects of nephrology practice. He has published over 200 articles and chapters.

 

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Is hemodiafiltration ready for broader use? Golper TA (2015) Kidney Int 88(5): 940-2
    › Primary publication · 26579679 (PubMed)
  2. Catheter Insertion and Perioperative Practices Within the ISPD North American Research Consortium. Wallace EL, Fissell RB, Golper TA, Blake PG, Lewin AM, Oliver MJ, Quinn RR (2016) Perit Dial Int 36(4): 382-6
    › Primary publication · 26493754 (PubMed) · PMC4934430 (PubMed Central)
  3. The intact nephron hypothesis in reverse: an argument to support incremental dialysis. Golper TA, Mehrotra R (2015) Nephrol Dial Transplant 30(10): 1602-4
    › Primary publication · 26163880 (PubMed)
  4. Intestinal Strongyloides causing peritoneal eosinophilia in peritoneal dialysis. Saha S, Sengsayadeth S, Golper TA (2012) Clin Kidney J 5(6): 579-81
    › Primary publication · 26069806 (PubMed) · PMC4400557 (PubMed Central)
  5. A critical shortage of solution threatens unprecedented growth in peritoneal dialysis. Blake PG, Golper TA, Saxena AB (2014) Nephrol News Issues 28(12): 14-6
    › Primary publication · 26016010 (PubMed)
  6. The PD solution crisis. Incremental peritoneal dialysis may be of particular value--right now. Golper TA, Saxena AB, Blake P (2014) Nephrol News Issues 28(12): 28-9
    › Primary publication · 26012118 (PubMed)
  7. Arteriovenous fistula creation may slow estimated glomerular filtration rate trajectory. Golper TA, Hartle PM, Bian A (2015) Nephrol Dial Transplant 30(12): 2014-8
    › Primary publication · 25888388 (PubMed) · PMC4832989 (PubMed Central)
  8. Automated cyclers used in peritoneal dialysis: technical aspects for the clinician. Chaudhry RI, Golper TA (2015) Med Devices (Auckl) : 95-102
    › Primary publication · 25653566 (PubMed) · PMC4311757 (PubMed Central)
  9. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system. Liu FX, Walton SM, Leipold R, Isbell D, Golper TA (2014) Perit Dial Int 34(7): 749-57
    › Primary publication · 25292402 (PubMed) · PMC4269500 (PubMed Central)
  10. Mind the gap. Golper TA, Fissell R (2014) J Am Soc Nephrol 25(9): 1893-5
    › Primary publication · 24854280 (PubMed) · PMC4147994 (PubMed Central)
  11. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Kalantar-Zadeh K, Unruh M, Zager PG, Kovesdy CP, Bargman JM, Chen J, Sankarasubbaiyan S, Shah G, Golper T, Sherman RA, Goldfarb DS (2014) Am J Kidney Dis 64(2): 181-6
    › Primary publication · 24840669 (PubMed) · PMC4111970 (PubMed Central)
  12. Does hemodialyzer reuse have a place in current ESRD care: "to be or not to be?". Denny GB, Golper TA (2014) Semin Dial 27(3): 256-8
    › Primary publication · 24649806 (PubMed) · PMC4086247 (PubMed Central)
  13. Comparative outcomes between continuous ambulatory and automated peritoneal dialysis: a narrative review. Bieber SD, Burkart J, Golper TA, Teitelbaum I, Mehrotra R (2014) Am J Kidney Dis 63(6): 1027-37
    › Primary publication · 24423779 (PubMed) · PMC4300314 (PubMed Central)
  14. The possible impact of the US prospective payment system ("bundle") on the growth of peritoneal dialysis. Golper TA (2013) Perit Dial Int 33(6): 596-9
    › Primary publication · 24335120 (PubMed) · PMC3862087 (PubMed Central)
  15. Amino acid losses during sustained low efficiency dialysis in critically ill patients with acute kidney injury. Umber A, Wolley MJ, Golper TA, Shaver MJ, Marshall MR (2014) Clin Nephrol 81(2): 93-9
    › Primary publication · 24290407 (PubMed)
  16. Hemodialysis: core curriculum 2014. Golper TA, Fissell R, Fissell WH, Hartle PM, Sanders ML, Schulman G (2014) Am J Kidney Dis 63(1): 153-63
    › Primary publication · 24268927 (PubMed) · PMC4276338 (PubMed Central)
  17. Dancing around elephants. Golper TA (2013) Clin J Am Soc Nephrol 8(10): 1643-4
    › Primary publication · 23970132 (PubMed) · PMC3789349 (PubMed Central)
  18. Is Dorothy correct? The role of patient education in promoting home dialysis. Golper TA, Mehrotra R, Schreiber MS (2013) Semin Dial 26(2): 138-42
    › Primary publication · 23520987 (PubMed)
  19. How to overcome barriers and establish a successful home HD program. Young BA, Chan C, Blagg C, Lockridge R, Golper T, Finkelstein F, Shaffer R, Mehrotra R, ASN Dialysis Advisory Group (2012) Clin J Am Soc Nephrol 7(12): 2023-32
    › Primary publication · 23037981 (PubMed) · PMC3513750 (PubMed Central)
  20. Nephrology quiz and questionnaire: renal replacement therapy. Golper TA, Discussant, Glassock RJ, Bleyer AJ (2012) Clin J Am Soc Nephrol 7(8): 1347-52
    › Primary publication · 22580784 (PubMed)
  21. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Matzke GR, Aronoff GR, Atkinson AJ, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P (2011) Kidney Int 80(11): 1122-37
    › Primary publication · 21918498 (PubMed)
  22. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators (2011) Clin J Am Soc Nephrol 6(10): 2499-507
    › Primary publication · 21903984 (PubMed) · PMC3359559 (PubMed Central)
  23. Systematic barriers to the effective delivery of home dialysis in the United States: a report from the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis. Golper TA, Saxena AB, Piraino B, Teitelbaum I, Burkart J, Finkelstein FO, Abu-Alfa A (2011) Am J Kidney Dis 58(6): 879-85
    › Primary publication · 21903316 (PubMed)
  24. Dialysate flow rate and delivered Kt/Vurea for dialyzers with enhanced dialysate flow distribution. Ward RA, Idoux JW, Hamdan H, Ouseph R, Depner TA, Golper TA (2011) Clin J Am Soc Nephrol 6(9): 2235-9
    › Primary publication · 21799145 (PubMed) · PMC3358998 (PubMed Central)
  25. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Marshall MR, Golper TA (2011) Semin Dial 24(2): 142-8
    › Primary publication · 21517979 (PubMed)
  26. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC (2011) Nephrol Dial Transplant 26(12): 3980-6
    › Primary publication · 21505096 (PubMed) · PMC3224113 (PubMed Central)
  27. Home dialysis in the new USA bundled payment plan: implications and impact. Golper TA, Guest S, Glickman JD, Turk J, Pulliam JP (2011) Perit Dial Int 31(1): 12-6
    › Primary publication · 21282384 (PubMed)
  28. The patient-centered medical home: managed care repackaged or something better? Wish J, Golper TA (2009) Nephrol News Issues 23(11): 56, 58, 60-2
    › Primary publication · 19911513 (PubMed)
  29. Technical breakthroughs in the wearable artificial kidney (WAK). Gura V, Macy AS, Beizai M, Ezon C, Golper TA (2009) Clin J Am Soc Nephrol 4(9): 1441-8
    › Primary publication · 19696219 (PubMed) · PMC2736696 (PubMed Central)
  30. Dialysate ... Ho-hum! Golper TA, Ward RA (2009) Clin J Am Soc Nephrol 4(9): 1403-4
    › Primary publication · 19696215 (PubMed)
  31. Learning about the practice of peritoneal dialysis. Golper TA (2009) Kidney Int 76(1): 12-4
    › Primary publication · 19528990 (PubMed)
  32. The financial implications for Medicare of greater use of peritoneal dialysis. Neil N, Guest S, Wong L, Inglese G, Bhattacharyya SK, Gehr T, Walker DR, Golper T (2009) Clin Ther 31(4): 880-8
    › Primary publication · 19446160 (PubMed)
  33. New challenges and paradigms for mid-career faculty in academic medical centers: key strategies for success for mid-career medical school faculty. Golper TA, Feldman HI (2008) Clin J Am Soc Nephrol 3(6): 1870-4
    › Primary publication · 18322049 (PubMed)
  34. Blood pressure targets in hemodialysis patients. Luther JM, Golper TA (2008) Kidney Int 73(6): 667-8
    › Primary publication · 18309346 (PubMed)
  35. Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clark JA, Schulman G, Golper TA (2008) Clin J Am Soc Nephrol 3(3): 736-42
    › Primary publication · 18272829 (PubMed) · PMC2386695 (PubMed Central)
  36. Predialysis nephrology care improves dialysis outcomes: now what? Or chapter two. Golper TA (2007) Clin J Am Soc Nephrol 2(1): 143-5
    › Primary publication · 17699398 (PubMed)
  37. Downloadable computer models for maintenance but not acute renal replacement therapy. Marshall MR, Golper TA (2006) Kidney Int 70(7): 1373-4; author reply 1374
    › Primary publication · 16988736 (PubMed)
  38. Drug-induced acute kidney injury. Schetz M, Dasta J, Goldstein S, Golper T (2005) Curr Opin Crit Care 11(6): 555-65
    › Primary publication · 16292059 (PubMed)
  39. The importance of residual renal function for patients on dialysis. Bargman JM, Golper TA (2005) Nephrol Dial Transplant 20(4): 671-3
    › Primary publication · 15755759 (PubMed)
  40. Hybrid renal replacement therapies for critically ill patients. Golper TA (2004) Contrib Nephrol : 278-83
    › Primary publication · 15264416 (PubMed)
  41. Frequency of physician visits to patients on in-center maintenance hemodialysis: does one strategy fit all? Golper TA (2004) J Am Soc Nephrol 15(1): 238-9
    › Primary publication · 14694179 (PubMed)
  42. Practice guidelines: are they dead on arrival? No, but.... Golper T (2003) Nephrol News Issues 17(11): 40-1
    › Primary publication · 14593819 (PubMed)
  43. L-carnitine treatment of anemia. Golper TA, Goral S, Becker BN, Langman CB (2003) Am J Kidney Dis 41(4 Suppl 4): S27-34
    › Primary publication · 12751051 (PubMed)
  44. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK (2002) Am J Kidney Dis 39(3): 556-70
    › Primary publication · 11877575 (PubMed)
  45. A summary of the 2000 update of the NKF-K/DOQI clinical practice guidelines on peritoneal dialysis adequacy. Golper TA, National Kidney Foundation (2001) Perit Dial Int 21(5): 438-40
    › Primary publication · 11757825 (PubMed)
  46. Chronic kidney disease: why is current management uncoordinated and suboptimal? Valderrábano F, Golper T, Muirhead N, Ritz E, Levin A (2001) Nephrol Dial Transplant : 61-4
    › Primary publication · 11590260 (PubMed)
  47. Patient education: can it maximize the success of therapy? Golper T (2001) Nephrol Dial Transplant : 20-4
    › Primary publication · 11590252 (PubMed)
  48. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK (2001) Kidney Int 60(2): 777-85
    › Primary publication · 11473662 (PubMed)
  49. Incremental dialysis. Golper TA (1998) J Am Soc Nephrol 9(12 Suppl): S107-11
    › Primary publication · 11443756 (PubMed)
  50. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Golper TA (2001) Contrib Nephrol (132): 349-53
    › Primary publication · 11395902 (PubMed)
  51. Hybrid renal replacement modalities for the critically ill. Marshall MR, Golper TA, Shaver MJ, Chatoth DK (2001) Contrib Nephrol (132): 252-7
    › Primary publication · 11395893 (PubMed)
  52. Dialysis modality distribution in the United States. Mendelssohn DC, Blake PG, Burkart J, Golper T, Oreopoulous D (2001) Am J Kidney Dis 37(6): 1330-1
    › Primary publication · 11382710 (PubMed)
  53. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National Kidney Foundation's Dialysis Outcomes Quality Initiative. Eknoyan G, Levin NW, Eschbach JW, Golper TA, Owen WF, Schwab S, Steinberg EP, Baylor College of Medicine, Renal Research Institute, Beth Israel Hospital Center, Minor & James Medical Center, Vanderbilt University, Duke University Medical Center, Covance Health Economics and Outcomes Services, Johns Hopkins University (2001) Am J Kidney Dis 37(1): 179-194
    › Primary publication · 11136186 (PubMed)
  54. Indications for vancomycin in dialysis patients. Golper TA, Schulman G, D'Agata EM (2000) Semin Dial 13(6): 389-92
    › Primary publication · 11130263 (PubMed)
  55. Are both creatinine and urea clearances necessary as indices of small solute clearance adequacy in peritoneal dialysis? Tzamaloukas AH, Golper TA (2000) ASAIO J 46(6): 651-3
    › Primary publication · 11110259 (PubMed)
  56. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S, International Society for Peritoneal Dialysis (2000) Perit Dial Int 20(4): 396-411
    › Primary publication · 11007371 (PubMed)
  57. Should we treat patients with incremental dialysis prescriptions? Burkart JM, Golper TA (2000) Blood Purif 18(4): 298-303
    › Primary publication · 10965071 (PubMed)
  58. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: description, findings, and implications. Steinberg EP, Eknoyan G, Levin NW, Eschbach JW, Golper TA, Owen WF, Schwab S (2000) Am J Kidney Dis 36(1): 1-11
    › Primary publication · 10873866 (PubMed)
  59. Impaired biological activity of erythropoietin by cyanate carbamylation. Mun KC, Golper TA (2000) Blood Purif 18(1): 13-7
    › Primary publication · 10686438 (PubMed)
  60. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G (1999) Br J Haematol 105(4): 938-41
    › Primary publication · 10554803 (PubMed)
  61. 17th annual meeting of the international society of blood purification Tesar V, Golper TA (1999) Blood Purif 17(4): 213-31
    › Primary publication · 10494024 (PubMed)
  62. The rationale for Healthy Start dialysis. Golper TA (1999) Blood Purif 17(1): 1-9
    › Primary publication · 10224333 (PubMed)
  63. Morbidity and mortality in redefining adequacy of peritoneal dialysis: a step beyond the National Kidney Foundation Dialysis Outcomes Quality Initiative. Chatoth DK, Golper TA, Gokal R (1999) Am J Kidney Dis 33(4): 617-32
    › Primary publication · 10196002 (PubMed)
  64. Indications, technical considerations, and strategies for renal replacement therapy in the intensive care unit. Golper TA (1992) J Intensive Care Med 7(6): 310-7
    › Primary publication · 10147940 (PubMed)
  65. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW (1999) Am J Kidney Dis 33(3): 507-17
    › Primary publication · 10070915 (PubMed)
  66. Implementation of the Peritoneal Dialysis Adequacy Guidelines: a personal perspective. Golper TA (1999) Adv Ren Replace Ther 6(1): 7-13
    › Primary publication · 9925144 (PubMed)
  67. Plasma iohexol clearance in automated peritoneal dialysis--its role in adequacy determination. Marx MA, Shuler CL, Golper TA (1998) Perit Dial Int 18(5): 512-5
    › Primary publication · 9848630 (PubMed)
  68. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Marx MA, Frye RF, Matzke GR, Golper TA (1998) Am J Kidney Dis 32(3): 410-4
    › Primary publication · 9740156 (PubMed)
  69. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Sloan RS, Kastan B, Rice SI, Sallee CW, Yuenger NJ, Smith B, Ward RA, Brier ME, Golper TA (1998) Am J Kidney Dis 32(2): 265-72
    › Primary publication · 9708611 (PubMed)
  70. Noncompliance in hemodialysis: predictors and survival analysis. Leggat JE, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK (1998) Am J Kidney Dis 32(1): 139-45
    › Primary publication · 9669435 (PubMed)
  71. Drug dosing adjustments during continuous renal replacement therapies. Golper TA, Marx MA (1998) Kidney Int Suppl : S165-8
    › Primary publication · 9573596 (PubMed)
  72. The rationale for improving outcomes on dialysis by actions prior to and at initiation. Golper TA (1998) Nephrol News Issues 12(2): 14-6
    › Primary publication · 9526365 (PubMed)
  73. Dose and adequacy. Golper TA, Twardowski ZJ, Warady BA, Lewy JE, Gotch FA, Firanek C, Eknoyan G (1997) Perit Dial Int : S40-1
    › Primary publication · 9304658 (PubMed)
  74. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Bunke CM, Brier ME, Golper TA (1997) Kidney Int 52(2): 524-9
    › Primary publication · 9264012 (PubMed)
  75. The Peritoneal Dialysis Multicenter Infection Study Project (MISP) under the auspices of the International Studies Committee of the International Society for Peritoneal Dialysis. Golper TA (1997) Perit Dial Int 17(3): 225-6
    › Primary publication · 9237279 (PubMed)
  76. Vancomycin revisited. Golper TA, Tranaeus A (1996) Perit Dial Int 16(2): 116-7
    › Primary publication · 9147541 (PubMed)
  77. Intermittent versus continuous antibiotics for PD-related peritonitis. Golper T (1997) Perit Dial Int 17(1): 11-2
    › Primary publication · 9068015 (PubMed)
  78. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Huang CC, Kawaguchi Y, Piraino B, Riella M, Schaefer F, Vas S (1996) Perit Dial Int 16(6): 557-73
    › Primary publication · 8981523 (PubMed)
  79. Relationship of dose of hemodialysis and cause-specific mortality. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ (1996) Kidney Int 50(2): 557-65
    › Primary publication · 8840286 (PubMed)
  80. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, Strife F, Hamburger RJ (1996) Am J Kidney Dis 28(3): 428-36
    › Primary publication · 8804243 (PubMed)
  81. Plasma iohexol clearance as an alternative to creatinine clearance for CAPD adequacy studies. Marx MA, Shuler CL, Tattersall JE, Golper TA (1995) Kidney Int 48(6): 1994-7
    › Primary publication · 8587263 (PubMed)
  82. Expanding indications for thrombolytic therapy. Dietz T, Talley JD, Hiller C, Golper TA (1995) J Ark Med Soc 92(5): 240-3
    › Primary publication · 8522500 (PubMed)
  83. Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi Y, Riella M, Vas S, Verbrugh HA (1993) Perit Dial Int 13(1): 14-28
    › Primary publication · 8443273 (PubMed)
  84. Case report: an unexpected intravenous pyelogram appearance in an azotemic patient. Gleason JR, Golper TA (1993) Am J Med Sci 305(2): 103-5
    › Primary publication · 8427290 (PubMed)
  85. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD. Bunke M, Bartlett DK, Brier ME, Golper TA (1993) Adv Perit Dial : 331-5
    › Primary publication · 8105957 (PubMed)
  86. Racial differences in the practice of peritoneal dialysis in Network 9. Golper TA, Brier ME (1993) Adv Perit Dial : 161-4
    › Primary publication · 8105914 (PubMed)
  87. Culture-negative CAPD peritonitis: the Network 9 Study. Bunke M, Brier ME, Golper TA (1994) Adv Perit Dial : 174-8
    › Primary publication · 7999821 (PubMed)
  88. Proinflammatory cytokines and hemofiltration membranes. Goldfarb S, Golper TA (1994) J Am Soc Nephrol 5(2): 228-32
    › Primary publication · 7994003 (PubMed)
  89. Continuous venovenous hemofiltration for acute renal failure in the intensive care setting. Technical considerations. Golper TA, Price J (1994) ASAIO J 40(4): 936-9
    › Primary publication · 7858329 (PubMed)
  90. Pseudomonas peritonitis in peritoneal dialysis patients: the Network #9 Peritonitis Study. Bunke M, Brier ME, Golper TA (1995) Am J Kidney Dis 25(5): 769-74
    › Primary publication · 7747731 (PubMed)
  91. Quality control in a peritoneal dialysis program. Golper TA (1995) Adv Ren Replace Ther 2(2): 143-7
    › Primary publication · 7614345 (PubMed)
  92. Drug therapy in renal failure: dosing guidelines for adults. Part II: sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents. Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I (1980) Ann Intern Med 93(2): 286-325
    › Primary publication · 7406382 (PubMed)
  93. Accidents with Tenckhoff catheters. Golper TA, Carpenter J (1981) Ann Intern Med 95(1): 121-2
    › Primary publication · 7247115 (PubMed)
  94. Acute renal failure and rhabdomyolysis after ingestion of phenylpropanolamine-containing diet pills. Swenson RD, Golper TA, Bennett WM (1982) JAMA 248(10): 1216
    › Primary publication · 7109141 (PubMed)
  95. Stability of antimicrobial agents in peritoneal dialysate. Sewell DL, Golper TA (1982) Antimicrob Agents Chemother 21(3): 528-9
    › Primary publication · 7103451 (PubMed) · PMC181931 (PubMed Central)
  96. Impaired renal mevalonate metabolism in nephrotic syndrome: a stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia. Golper TA, Swartz SH (1982) Metabolism 31(5): 471-6
    › Primary publication · 7078427 (PubMed)
  97. Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics. Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I (1980) Ann Intern Med 93(1): 62-89
    › Primary publication · 6994534 (PubMed)
  98. Nontuberculous mycobacterial peritonitis associated with continuous ambulatory peritoneal dialysis. Pulliam JP, Vernon DD, Alexander SR, Hartstein AI, Golper TA (1983) Am J Kidney Dis 2(6): 610-4
    › Primary publication · 6846333 (PubMed)
  99. Percutaneous aspiration biopsy of renal allografts using ultrasound localization. Parker RA, Elliott WC, Muther RS, Golper TA, Barry JM, Henderson SC, Bennett WM (1980) Urology 15(5): 534-5
    › Primary publication · 6763398 (PubMed)
  100. Complications of percutaneous needle biopsy of the kidney. Wickre CG, Golper TA (1982) Am J Nephrol 2(4): 173-8
    › Primary publication · 6756144 (PubMed)
  101. Incomplete activation of intraperitoneal clindamycin phosphate during peritoneal dialysis. Golper TA, Sewell DL, Fisher PB, Wolfson M (1984) Am J Nephrol 4(1): 38-42
    › Primary publication · 6731498 (PubMed)
  102. Therapy for uremic hyperlipidemia. Golper TA (1984) Nephron 38(4): 217-25
    › Primary publication · 6392912 (PubMed)
  103. Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Sewell DL, Golper TA, Brown SD, Nelson E, Knower M, Kimbrough RC (1983) Am J Kidney Dis 3(3): 209-12
    › Primary publication · 6356893 (PubMed)
  104. Drug prescribing in renal failure: dosing guidelines for adults. Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I (1983) Am J Kidney Dis 3(3): 155-93
    › Primary publication · 6356890 (PubMed)
  105. Efficacy of minoxidil in the treatment of severe hypertension in systemic disorders. Bennett WM, Golper TA, Muther RS, McCarron DA (1980) J Cardiovasc Pharmacol : S142-8
    › Primary publication · 6156349 (PubMed)
  106. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Golper TA, Wedel SK, Kaplan AA, Saad AM, Donta ST, Paganini EP (1985) Int J Artif Organs 8(6): 307-12
    › Primary publication · 4077288 (PubMed)
  107. Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Golper TA, Pulliam J, Bennett WM (1985) Arch Intern Med 145(9): 1651-2
    › Primary publication · 4026495 (PubMed)
  108. Diagnostic value of creatine kinase and creatine kinase MB isoenzyme in chronic hemodialysis patients: a longitudinal study. Green TR, Golper TA, Swenson RD, Pulliam JP, Morris CD (1986) Clin Nephrol 25(1): 22-7
    › Primary publication · 3955905 (PubMed)
  109. Continuous arteriovenous hemofiltration in acute renal failure. Golper TA (1985) Am J Kidney Dis 6(6): 373-86
    › Primary publication · 3907333 (PubMed)
  110. Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters. Golper TA, Saad AM (1986) Kidney Int 30(6): 937-43
    › Primary publication · 3820943 (PubMed)
  111. The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat. Golper TA, Feingold KR, Fulford MH, Siperstein MD (1986) J Lipid Res 27(10): 1044-51
    › Primary publication · 3794548 (PubMed)
  112. Early experience with continuous arteriovenous hemofiltration in critically ill pediatric patients. Leone MR, Jenkins RD, Golper TA, Alexander SR (1986) Crit Care Med 14(12): 1058-63
    › Primary publication · 3780250 (PubMed)
  113. A multicenter trial to evaluate the use of the CAPD "O" set. Lempert KD, Kolb JA, Swartz RD, Campese V, Golper TA, Winchester JF, Nolph KD, Husserl FE, Zimmerman SW, Kurtz SB (1986) ASAIO Trans 32(1): 557-9
    › Primary publication · 3778768 (PubMed)
  114. Transmembrane pressures generated by filtrate line suction maneuvers and predilution fluid replacement during in vitro continuous arteriovenous hemofiltration. Golper TA, Kaplan AA, Narasimhan N, Leone M (1987) Int J Artif Organs 10(1): 41-6
    › Primary publication · 3570541 (PubMed)
  115. Clinical characteristics and diagnostic considerations in acquired renal cystic disease. Narasimhan N, Golper TA, Wolfson M, Rahatzad M, Bennett WM (1986) Kidney Int 30(5): 748-52
    › Primary publication · 3537463 (PubMed)
  116. Analysis of the causative pathogens in uncomplicated CAPD-associated peritonitis: duration of therapy, relapses, and prognosis. Golper TA, Hartstein AI (1986) Am J Kidney Dis 7(2): 141-5
    › Primary publication · 3511680 (PubMed)
  117. Sieving characteristics of a new polysulfone hemofilter for use with continuous arterio-venous hemofiltration. Kaplan AA, Golper TA (1987) Int J Artif Organs 10(6): 357-60
    › Primary publication · 3443518 (PubMed)
  118. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Golper TA, Hartstein AI, Morthland VH, Christensen JM (1987) Antimicrob Agents Chemother 31(11): 1787-90
    › Primary publication · 3435126 (PubMed) · PMC175040 (PubMed Central)
  119. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM (1988) Antimicrob Agents Chemother 32(6): 844-7
    › Primary publication · 3415205 (PubMed) · PMC172293 (PubMed Central)
  120. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Golper TA, Noonan HM, Elzinga L, Gilbert D, Brummett R, Anderson JL, Bennett WM (1988) Clin Pharmacol Ther 43(5): 565-70
    › Primary publication · 3365918 (PubMed)
  121. Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM (1987) Kidney Int 32(6): 884-8
    › Primary publication · 3123761 (PubMed)
  122. Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients. Golper TA, Bennett WM (1988) Med Toxicol Adverse Drug Exp 3(5): 341-9
    › Primary publication · 3057325 (PubMed)
  123. Backtransport of dialysate solutes during in vitro continuous arteriovenous hemodialysis. Golper TA, Leone M (1989) Blood Purif 7(4): 223-9
    › Primary publication · 2775515 (PubMed)
  124. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Golper TA, Illingworth DR, Morris CD, Bennett WM (1989) Am J Kidney Dis 13(4): 312-20
    › Primary publication · 2650539 (PubMed)
  125. Comparison of two commercial broth-culture systems for microbial detection in dialysates of patients on continuous ambulatory peritoneal dialysis. Saubolle MA, Sewell DL, Holland MD, Golper TA (1989) Diagn Microbiol Infect Dis 12(6): 457-61
    › Primary publication · 2625034 (PubMed)
  126. Reduction of cyst volume for symptomatic management of autosomal dominant polycystic kidney disease. Bennett WM, Elzinga L, Golper TA, Barry JM (1987) J Urol 137(4): 620-2
    › Primary publication · 2435925 (PubMed)
  127. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD (1990) Kidney Int 38(5): 912-8
    › Primary publication · 2266675 (PubMed)
  128. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD (1990) Kidney Int 38(5): 904-11
    › Primary publication · 2266674 (PubMed)
  129. The treatment of anemia with low-dose recombinant human erythropoietin. Aronoff GR, Duff DR, Sloan RS, Brier ME, Maurice B, Erickson B, Golper TA (1990) Am J Nephrol : 40-3
    › Primary publication · 2260617 (PubMed)
  130. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. Sewell DL, Golper TA, Hulman PB, Thomas CM, West LM, Kubey WY, Holmes CJ (1990) Perit Dial Int 10(1): 49-52
    › Primary publication · 2128189 (PubMed)
  131. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR (1991) Am J Kidney Dis 18(1): 60-4
    › Primary publication · 2063856 (PubMed)
  132. Continuous arteriovenous hemofiltration in the critically ill patient. Warnholtz A, Slater AD, Golper TA (1991) J Ky Med Assoc 89(3): 111-4
    › Primary publication · 2026931 (PubMed)
  133. The effect of tobramycin on the renal handling of vancomycin. Munar MY, Elzinga L, Brummett R, Golper TA, Bennett WM (1991) J Clin Pharmacol 31(7): 618-23
    › Primary publication · 1894757 (PubMed)
  134. The role of convection during simulated continuous arteriovenous hemodialysis. Golper TA, Cigarran-Guldris S, Jenkins RD, Brier ME (1991) Contrib Nephrol : 146-8
    › Primary publication · 1802567 (PubMed)
  135. Tobramycin clearance during simulated continuous arteriovenous hemodialysis. Cigarran-Guldris S, Brier ME, Golper TA (1991) Contrib Nephrol : 120-3
    › Primary publication · 1802559 (PubMed)
  136. Drug removal during continuous hemofiltration or hemodialysis. Golper TA (1991) Contrib Nephrol : 110-6
    › Primary publication · 1802557 (PubMed)
  137. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. Besarab A, Golper TA (1991) ASAIO Trans 37(3): M395-6
    › Primary publication · 1751205 (PubMed)
  138. Ciprofloxacin and plasmids in staphylococci. Hartstein AI, Morthland V, Golper TA, Rashad AL (1991) J Antimicrob Chemother 27(1): 141-4
    › Primary publication · 1675634 (PubMed)
  139. The effect of recombinant erythropoietin on the early hematocrit rise after CAPD initiation. Golper TA (1992) Perit Dial Int 12(1): 37-9
    › Primary publication · 1543778 (PubMed)
  140. Guidelines for drug therapy in renal failure. Bennett WM, Singer I, Golper T, Feig P, Coggins CJ (1977) Ann Intern Med 86(6): 754-83
    › Primary publication · 869359 (PubMed)
  141. Intestinal bypass and urine oxalate. Golper TA, Harris HF, Houghton DC (1979) Ann Intern Med 91(1): 129-30
    › Primary publication · 464435 (PubMed)
  142. Primary cadaver kidney transplantation in older patients: survival equal to dialysis. Golper TA, Barry JM, Bennett WM, Porter GA (1978) Trans Am Soc Artif Intern Organs : 282-7
    › Primary publication · 362674 (PubMed)
  143. Adrenocorticotropin-cortisol axis abnormalities in hemodialysis patients. McDonald WJ, Golper TA, Mass RD, Kendall JW, Porter GA, Girard DE, Fischer MD (1979) J Clin Endocrinol Metab 48(1): 92-5
    › Primary publication · 217891 (PubMed)
  144. Glucagonoma syndrome in a 19-year-old woman. Riddle MC, Golper TA, Fletcher WS, Ensinck JW, Smith PH (1978) West J Med 129(1): 68-72
    › Primary publication · 210595 (PubMed) · PMC1238245 (PubMed Central)